Participant, Site Personnel and Sponsor Perspectives on Decentralized Trial Features in COURAGE-ALS: a Randomized Clinical Trial

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

Hospitalizations as an Outcome Measure in COURAGE-ALS

A Plain Language Summary of the SEQUOIA-HCM Study: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

The Effect of Omecamtiv Mecarbil on Outcomes Analysed Using the Win Ratio: an Exploratory Analysis of GALACTIC-HF

Effect of Aficamten Treatment on Patients with Hypertrophic Obstructive Cardiomyopathy by Geographical Region

Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms

Efficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUIOA-HCM Trial

Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants

Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy